Janux Therapeutics (JANX) Research & Development (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Research & Development data on file, last reported at $26.8 million in Q1 2026.

• Research & Development for Q1 2026 came in at $26.8 million, up 7.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $127.7 million (up 60.83% YoY), and the FY2025 annual result was $125.9 million, up 84.09% from the prior year.
• Research & Development slipped to $26.8 million in Q1 2026 per JANX's latest filing, from $31.5 million in the prior quarter.
• Over five years, Research & Development peaked at $34.7 million in Q2 2025 and troughed at $10.2 million in Q1 2022.
• A 5-year average of $19.4 million and a median of $15.4 million in 2022 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2023: Research & Development soared 429.04% in 2022, then declined 20.69% in 2023.
• A 5-year view of Research & Development shows it stood at $15.4 million in 2022, then decreased by 20.69% to $12.2 million in 2023, then jumped by 69.97% to $20.8 million in 2024, then jumped by 51.63% to $31.5 million in 2025, then declined by 15.01% to $26.8 million in 2026.
• Business Quant data shows JANX's Research & Development at $26.8 million in Q1 2026, $31.5 million in Q4 2025, and $34.6 million in Q3 2025.